Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2008

Open Access 01-06-2008 | Research article

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer

Authors: Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin

Published in: Breast Cancer Research | Issue 3/2008

Login to get access

Abstract

Introduction

Neoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy response and aid in the development of individualized treatment regimens. Multianalyte profiles may offer greater predictive power for neoadjuvant treatment response than the individual biomarkers currently in use.

Methods

Serum samples were collected from 44 patients enrolled in a phase I–II, open-label study of liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia for the neoadjuvant treatment of locally advanced breast cancer (stage IIB or stage III). Samples were collected prior to each of four rounds of treatment and prior to definitive surgery. Samples were assayed by Luminex assay for 55 serum biomarkers, including cancer antigens, growth/angiogenic factors, apoptosis-related molecules, metastasis-related molecules, adhesion molecules, adipokines, cytokines, chemokines, hormones, and other proteins.

Results

Biomarker levels were compared retrospectively with clinical and pathologic treatment responses. Univariate analysis of the data identified several groups of biomarkers that differed significantly among treatment outcome groups early in the course of neoadjuvant chemotherapy. Multivariate statistical analysis revealed multibiomarker panels that could differentiate between treatment response groups with high sensitivity and specificity.

Conclusion

We demonstrate here that serum biomarker profiles may offer predictive power concerning treatment response and outcome in the neoadjuvant setting. The continued development of these findings will be of considerable clinical utility in the design of treatment regimens for individual breast cancer patients.

Trial registration

#NCT00346229.
Appendix
Available only for authorised users
Literature
1.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin N Am. 2003, 83: 803-819. 10.1016/S0039-6109(03)00034-3.CrossRefPubMed
2.
Lee MC, Newman LA: Management of patients with locally advanced breast cancer. Surg Clin N Am. 2007, 87: 379-398. 10.1016/j.suc.2007.01.012.CrossRefPubMed
3.
4.
Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987, 47: 3889-3894.PubMed
5.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001, 30: 96-102.CrossRef
6.
Giordano SH: Update on locally advanced breast cancer. The Oncologist. 2003, 8: 521-530. 10.1634/theoncologist.8-6-521.CrossRefPubMed
7.
Hanrahan EO, Hennessy BT, Valero V: Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 2005, 6: 1477-1491. 10.1517/14656566.6.9.1477.CrossRefPubMed
8.
Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I, Ford HT: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995, 13: 547-552.CrossRefPubMed
9.
Hage van der JA, Velde van de CJ, Julien JP, Floiras JL, Delozier T, Vandervelden C, Duchateau L: Improved survival after one course of perioperative chemotherapy in early breast cancer patients: long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer. 2001, 37: 2184-2193. 10.1016/S0959-8049(01)00294-5.CrossRefPubMed
10.
De Lena M, Varini M, Zucali R, Rovini D, Viganotti G, Valagussa P, Veronesi U, Bonadonna G: Multimodal treatment for locally advanced breast cancer. Result of chemotherapy–radiotherapy versus chemotherapy–surgery. Cancer Clin Trials. 1981, 4: 229-236.PubMed
11.
Papaioannou A, Lissaios B, Vasilaros S, Miligos S, Papadimitriou G, Kondilis D, Polychronis A, Kozonis J, Papageorgiou G, Plataniotis G, Razis D, Stathopoulos G, Tsiliakos S, Throuvhlas N, Papavasiliou K, Tsarouhas C, Papaevangelou G: Pre- and postoperative chemoendocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer. Cancer. 1983, 51: 1284-1290. 10.1002/1097-0142(19830401)51:7<1284::AID-CNCR2820510718>3.0.CO;2-M.CrossRefPubMed
12.
Charfare H, Limongelli S, Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005, 92: 14-23. 10.1002/bjs.4840.CrossRefPubMed
13.
Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005, 23: 9304-9311. 10.1200/JCO.2005.02.5023.CrossRefPubMed
14.
Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG, Montague E: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988, 62: 2507-2516. 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D.CrossRefPubMed
15.
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986, 46: 2578-2581.PubMed
16.
Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ: Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci USA. 2007, 104: 4014-4019. 10.1073/pnas.0611058104.CrossRefPubMedPubMedCentral
17.
Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M: Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?. J Surg Oncol. 2007, 96: 474-480. 10.1002/jso.20856.CrossRefPubMed
18.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003, 362: 362-369. 10.1016/S0140-6736(03)14023-8.CrossRefPubMed
19.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005, 23: 7265-7277. 10.1200/JCO.2005.02.0818.CrossRefPubMed
20.
Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F: Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol. 2003, 14: 428-432. 10.1093/annonc/mdg104.CrossRefPubMed
21.
Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001, 61: 2505-2512.PubMed
22.
Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003, 39: 631-634. 10.1016/S0959-8049(02)00745-1.CrossRefPubMed
23.
Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, Higgins NO: CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006, 6: 220-226. 10.1186/1471-2407-6-220.CrossRefPubMedPubMedCentral
24.
Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P: Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002, 52: 397-405.CrossRefPubMed
25.
Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, Brizel DM, Vujaskovic Z: Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res. 2004, 10: 4287-4293. 10.1158/1078-0432.CCR-04-0133.CrossRefPubMed
26.
27.
Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 981-987. 10.1158/1055-9965.EPI-04-0404.CrossRefPubMed
28.
Sarkar M, Leong TY: Application of K-nearest neighbors algorithm on breast caner diagnosis problem. Proc AMIA Symp. 2000, 759-763.
29.
Hastie T, Tibshirani R, Friedman J: The Elements of Statistical Learning. 2001, Springer; 233 Spring St., NY 10013, USACrossRef
30.
Devroye L, Gyorfi L, Lugosi G: A Probabilistic Theory of Pattern Recognition. 1996, Springer; 233 Spring St., NY 10013, USACrossRef
31.
Furnival G, Wilson R: Regressions by leaps and bounds. Technometrics. 1974, 16: 499-511. 10.2307/1267601.CrossRef
32.
33.
Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S: Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?. Neoplasma. 2007, 54: 348-352.PubMed
34.
Martinez-Trufero J, de Lobera AR, Lao J, Puertolas T, Artal-Cortes A, Zorrilla M, Alonso V, Pazo R, Valero MI, Rios-Mitchell MJ, Calderero V, Herrero A, Antón A: Serum markers and prognosis in locally advanced breast cancer. Tumori. 2005, 91: 522-530.PubMed
35.
Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, Samonigg H, Bauernhofer T: The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol. 2007, 128: 630-637. 10.1309/51KPD70348RP6XTE.CrossRefPubMed
36.
Sliwowska I, Kopczynski Z, Grodecka-Gazdecka S: Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Postepy Hig Med Dosw (Online). 2006, 60: 295-299.
37.
Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY: Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004, 10: 7157-7162. 10.1158/1078-0432.CCR-04-0812.CrossRefPubMed
38.
Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003, 48: 82-84.PubMed
39.
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN: Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004, 25: 94-102. 10.1016/j.cyto.2003.10.004.CrossRefPubMed
40.
Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M, Matache C: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006, 10: 499-510. 10.1111/j.1582-4934.2006.tb00415.x.CrossRefPubMed
41.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007, 96: 903-911. 10.1038/sj.bjc.6603666.CrossRefPubMedPubMedCentral
42.
Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000, 60: 636-643.PubMed
43.
Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Janicke F, Thomssen C: Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer. 2002, 3: 196-200.CrossRefPubMed
44.
Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Hofler H, Kiechle M, Schmitt M, Harbeck N: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003, 21: 1022-1028. 10.1200/JCO.2003.04.170.CrossRefPubMed
45.
Ibrahim YH, Yee D: Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res. 2005, 11 (2 Pt 2): 944s-950s.PubMed
46.
Portier CJ: Endocrine dismodulation and cancer. Neuro Endocrinol Lett. 2002, 23 (Suppl 2): 43-47.PubMed
47.
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007, 26: 5046-5059. 10.1038/sj.onc.1210318.CrossRefPubMed
48.
Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002, 8: 3454-3460.PubMed
49.
Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev. 1992, 13: 3-17. 10.1210/er.13.1.3.
50.
Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, Ogawa Y, Taguchi T: Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer. 2004, 11: 389-395.CrossRefPubMed
51.
Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer. 2007, 7: 36-45. 10.1186/1471-2407-7-36.CrossRefPubMedPubMedCentral
52.
Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A: Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 2007, 107: 58-65. 10.1016/j.ygyno.2007.05.041.CrossRefPubMedPubMedCentral
53.
Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL: Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007, 16: 102-107. 10.1158/1055-9965.EPI-06-0602.CrossRefPubMed
Metadata
Title
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Authors
Brian M Nolen
Jeffrey R Marks
Shlomo Ta'san
Alex Rand
The Minh Luong
Yun Wang
Kimberly Blackwell
Anna E Lokshin
Publication date
01-06-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2096

Other articles of this Issue 3/2008

Breast Cancer Research 3/2008 Go to the issue

Research article

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors

Research article

Breast cancer tumor growth estimated through mammography screening data

Letter

The future of mammary stem cell biology: the power of in vivotransplants – authors' response

Research article

The CD44+/CD24-phenotype is enriched in basal-like breast tumors

Research article

Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/-mice

Research article

Jab1 is a target of EGFR signaling in ERα-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits